Suppr超能文献

接受体外光化学疗法治疗的系统性硬化症患者的肺癌发病率。

Incidence of lung cancer in patients with systemic sclerosis treated with extracorporeal photopheresis.

作者信息

Topuzoglu Sabriye, Knobler Robert, Movadat Oliver, Petkov Ventzislav, Foedinger Dagmar, Just Ulrike, Pehamberger Hubert, Jantschitsch Christian

机构信息

Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Vienna, Austria.

Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

出版信息

Photodermatol Photoimmunol Photomed. 2015 Jul;31(4):175-83. doi: 10.1111/phpp.12155. Epub 2015 Jan 15.

Abstract

BACKGROUND

Extracorporeal photopheresis (ECP) improves skin sclerosis in systemic sclerosis (SSc) patients. SSc is associated with an increased risk of lung cancer. As ECP is supposed to exert immunomodulatory effects, a possible impact of ECP on the incidence of lung cancer in SSc patients was evaluated.

METHODS

Seventy-one SSc patients treated with ECP at the Photopheresis Unit of the Department of Dermatology at the Medical University of Vienna between 1991 and 2013 were analyzed retrospectively.

RESULTS

We calculated a standardized incidence ratio (SIR) for lung cancer in ECP-treated SSc patients of 2.34 [95% confidence interval (CI) 1.63-2.49]. This is in accordance with recent meta-analyses demonstrating a significantly enhanced risk of lung carcinoma in SSc patients. Comparison of the lung cancer risks of these patients with our ECP-treated patients revealed that ECP has no influence. Each patient with lung carcinoma had previously been diagnosed with lung involvement of the non-specific interstitial pneumonitis (NSIP) type.

CONCLUSION

We confirm that SSc patients are at significantly increased risk for lung cancer. However, ECP does not influence this risk. NSIP may be a risk factor for lung cancer in SSc patients.

摘要

背景

体外光化学疗法(ECP)可改善系统性硬化症(SSc)患者的皮肤硬化。SSc与肺癌风险增加相关。由于ECP被认为具有免疫调节作用,因此评估了ECP对SSc患者肺癌发病率的可能影响。

方法

回顾性分析了1991年至2013年间在维也纳医科大学皮肤科光化学疗法科接受ECP治疗的71例SSc患者。

结果

我们计算出接受ECP治疗的SSc患者肺癌的标准化发病比(SIR)为2.34 [95%置信区间(CI)1.63 - 2.49]。这与最近的荟萃分析结果一致,该分析表明SSc患者患肺癌风险显著增加。将这些患者与接受ECP治疗的患者的肺癌风险进行比较后发现,ECP没有影响作用。每例肺癌患者之前均被诊断为非特异性间质性肺炎(NSIP)型肺部受累。

结论

我们证实SSc患者患肺癌的风险显著增加。然而,ECP不会影响这一风险。NSIP可能是SSc患者患肺癌的一个风险因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验